Clinical trials: Symptomatic Dermographism
Chronic Inducible Urticaria, Cold Urticaria
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
The purpose of this Phase 3, randomized, double-blind, placebo-controlled study is to assess the activity and safety of barzolvolimab compared to placebo in participants with cold induced urticaria or symptomatic dermographism…
- Conditions
- Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
- Trial name
- NCT07266402
- Testing
- Barzolvolimab
- Where
- 72 sites in United States, Germany and 5 more
- Volunteers
- 240 people
- Sponsor
- Celldex Therapeutics
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in participants with Chronic Urticaria (CU), including both Chronic Spontaneous Urticaria…
- Trial name
- NCT06865651
- Testing
- Remibrutinib
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Cold Urticaria, Cold Contact Urticaria
A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
This is a study to determine the safety of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria.
- Conditions
- Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism, Symptomatic Dermatographism
- Trial name
- NCT04548869
- Testing
- CDX-0159
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Celldex Therapeutics
Healthy Subjects, Cold Urticaria
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.
- Conditions
- Healthy Subjects, Cold Urticaria, Symptomatic Dermographism, Chronic Inducible Urticaria
- Trial name
- CHILL-MC (NCT07181369)
- Testing
- GTX-B001, Normal Saline
- Where
- 3 sites in Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Granular Therapeutics Limited
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants…
- Trial name
- NCT06931405
- Testing
- BLU-808
- Where
- 47 sites in United States, Denmark and 4 more
- Volunteers
- 105 people
- Sponsor
- Blueprint Medicines Corporation
Chronic Inducible Urticaria
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
This was a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1-antihistamines
- Trial name
- PEARL-PROVOKE (NCT05024058)
- Testing
- Ligelizumab
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals